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IL-2 is a 15,000-dalton glycoprotein that is secreted by T lymphocytes . IL-2 binds
to a membrane receptor on lymphocytes and monocytes and initiates activation,
proliferation, and differentiation by a process that has not been completely delineated
(1) . The IL-2R is composed of at least two subunits, the p55 (CD25/Tai) and p75
glycoproteins (2-4) . The p55 subunit binds IL-2 with low affinity (Kd -10-8) and
the p75 subunit binds with intermediate affinity (Kd N10-9
), whereas a dimeric
receptor composed of both p55 and P75 binds IL-2 with high affinity (Kd N10-12)
(2-4) . Cells may express p55 alone, p75 alone, or both subunits (2-4) . p75 IL-2R
is responsible for signal transduction, whereas p55 primarily functions to create a
high affinity receptor by association with p75 (5, 6) .
Human peripheral blood NK cells (CD3-CD16+ lymphocytes) are rapidly acti-
vated by IL-2, resulting in augmented cytotoxic activity, induction of activation an-
tigens, and proliferation (7-9) . RestingNK cellsdo not express p55 IL-2R (CD25),
suggesting that the response is mediated by another IL-2 binding protein (7, 8) .
Biochemical crosslinking experiments using 1251-labeled IL-2 have demonstrated the
presence of 70/75-kD proteins on themembrane ofNK cells (10, 11) . Recently, mAbs
have been produced against the p75 IL-2R (12, 13) . Thus, it is now possible to directly
assess the expression and function of this structure in IL-2-mediated activation . In
the present study, we have examined the role of the P75 and p55 IL-2R inNK cell
activation .
Materials and Methods
Cell Culture.
￿
PBMC were isolated using Ficoll/Hypaque . After plastic adherence and pas-
sage through nylon wool to remove monocytes and B cells, respectively, lymphocytes were
fractionated by centrifugation on discontinuous gradients consisting of 30 and 40% Percoll
(Pharmacia Fine Chemicals, Piscataway, NJ), as described (14) . Low buoyant density cells
isolated from the interface of Percoll gradients consisted of -40-50% NK cells (CD3- ,
CD16') and 50-60% T cells (CD3', CD16-) . Cells were cultured in RPMI 1640 (M . A . Bio-
products, Walkersville, MD), 4% heat-inactivated horse serum (KC Biologicals, Lexena, KS),
1MM L-glutamine (Gibco Laboratories, Chagrin Falls, OH), and antibiotics . rIL-2 was gener-
ously provided by Cetus Corp., Emeryville, CA . For proliferation assays, cells were cultured
in 96-well microtiter plates and were harvested on day 4, after overnight labeling with
[ 3H]thymidine (1 tiCi/well) (Amersham Corp., Arlington Heights, IL).
Monoclonal Antibodies .
￿
TU27 mAb reacts with the p75 subunit of the IL-2R and inhibits
the binding of IL-2 to the receptor (12) . Anti-IL-2R (CD25) (clone 2A3) reacts with the p55
subunit of the IL-2R . Leu series mAbs were produced by Becton Dickinson Monoclonal
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Center, Inc . Phycoerythrin (PE)-conjugated rat anti-mouse IgGI mAb andanti-Leu 23 mAb
were generously provided by Mr. David Buck and Dr. Anne Jackson (Becton Dickinson),
respectively.
Immuno .fluorescence andFlow Cytometry.
￿
Immunofluorescence and flow cytometrywere per-
formed as described (15) . Samples were analyzed usingaFACScan and cell sortingwas per-
formed using a FACS IV (Becton Dickinson Immunocytometry Systems, SanJose, CA).
Cytotoxicity.
￿
Cytotoxicity was measured by a 4-h "Cr-release assay using the NK-resistant
Colo-205 colon carcinoma cell line as target (14) .
Results and Discussion
Preferential Expression ofp75 IL-2R on NK Cells .
￿
Peripheral blood leukocytes were
stained with anti-p75 IL-2RmAb to determine distribution ofthis receptor on normal,
resting cells. p75 IL-2R was detectedon a small proportion ofperipheral blood lym-
phocytes (5-1517o of lymphocytes, depending on the donor), but was not detected
on monocytes or granulocytes (Fig . 1 A) . Within the lymphocyte population, p75
IL-2R was expressed preferentially on CD16+ NK cells (Fig . 1 B) . Examination of
the contour plot correlating CD16 and p75 IL-2R indicated that essentially all
CD16+ NK cells expressed low levels of this antigen, whereas few (<5%) of C1316-
lymphocytes, includingB andT lymphocytes, demonstrated detectable levels ofp75
IL-2R. In most donors, CD16 is expressed exclusively on CD3- NK cells, and is
not present onT or B lymphocytes (15) . Consistent with prior reports (7, 8), p55
IL-2R was not detected on CD16+ NK cells (not shown) . Expression of p75 IL-2R
onNK cells, but not a substantial proportion ofB orT lymphocytes, was observed
in more than 10 normal donors .
Affect ofAnti-p75IL-2RmAbonNK CellActivation, Cytotoxicity, and Proliferation.
￿
The
finding that NK cells constitutively express p75 IL-2R is consistent with prior ob-
servations that IL-2 alone preferentially activates resting, peripheral bloodNK cells
(7, 8, 10), but not a substantial proportion ofT or B lymphocytes . Stimulation of
FIGURE 1 .
￿
Expression ofp75 IL-2Ron NK
cells . Peripheral blood leukocytes were stained
with FITC-conjugated IgG2a control mAb
and control purified IgGl mAbor FITC con-
jugated anti-Leu-lld (CD16) (IgG2a mAb)
and purified anti-p75 IL-2R (IgG1 mAb) . PE-
conjugated rat anti-mouse IgG1 mAb was
usedto detect anti-p75 IL-2RmAb . Samples
were analyzed using a FACScan . Based on
characteristic forward and wide angle light
scatter patterns, electronic gates were set on
lymphocytes, monocytes, and granulocytes,
as indicated . (A) Histograms of anti-p75 IL-
2R-stained cells were superimposed over
histograms of control Ig stained cells (histo-
grams nearest the ordinate) . (B)Contour plots
of lymphocytes stained with fluorochrome-
conjugated control IgorFITC anti-CD16and
anti-p75 IL-2R, followed by PE conjugated
anti-mouse IgGI . Markers defining quadrants
were positioned to include>98% of the con-
trol IgG stainedcells in thelower left quadrant.PHILLIPS ET AL .
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NK cells with rIL-2 in vitro results in the induction of activation antigens, the ac-
quisition of cytotoxic activity against NK-resistant tumors (i.e ., LAK activity), and
proliferation (8, 9, 14, 16) . An increased number and proportion of circulatingNK
cells expressing activation antigens and enhanced cytolytic activity have also been
noted in patients treated with rIL-2 in vivo (17) . Based on indirect evidence, it has
been suggested that the effect of IL-2 on NK cells is mediated through the p75 IL-
2R (10, 11) . However, in addition to the 75-kD IL-2R, a 70-kD protein is also de-
tected by crosslinking 1251-IL-2 to the membrane of NK cells (10, 11) and other
membrane structures, e.g ., HLA (18) and OKT27 (19), have been shown to be as-
sociated with IL-2 binding . Therefore, further studies were undertaken to deter-
mine the effect of anti-p75 IL-2R mAb on activation ofNK cells by IL-2 .
Resting, peripheral blood low buoyant density lymphocytes, enriched forNK cells,
(Fig . 2, A, B) or FRCS-purified CD3-CD16' NK cells (Fig . 2, C, D) were cultured
FIGURE 2 .
￿
Effects ofanti-IL-2R mAbs on NK cells cytotoxicity and proliferation . (A, B) Low
buoyant density peripheral blood lymphocytes, enriched for NK cells (N40% CD3 - , CD16'),
were cultured in various concentrations of rIL-2 in the presence or absence of isotype-matched
control Ig (A, "; B, 0), anti-p55 IL2-R(A, O; B, ®), anti-p75 IL-2R (A, p ; B, ®), or both
anti-p55 IL-2Rand anti-P75 IL2-R (A, M; B, ®) (mAb concentration, 10 Wg/ml) . (C, D) FRCS
purified (>97%) CD3- ,CD16' NK cells were cultured with 200 U/ml rIL-2 in the presence
or absence of isotype-matched control Ig, anti-p55 IL2-R and/or anti-p75 IL-2R(mAb concen-
tration, 10 Wg/ml), as indicated . Cytotoxicity against the NK-resistant Colo-205 cell lines was
assayed after 18 h culture (A, C),and proliferation was assessed after 4d (B, D) . For proliferation
assays, cells were plated at 5 x 10 6/ml (B) or 5 x 104 cells/ml (D) .294
￿
PHILLIPS ET AL.
￿
BRIEF DEFINITIVE REPORT
with rIL-2 in the presence or absence of anti-p75 IL-2Rand/or anti-p55 IL-2R mAb.
As shown in Fig. 2 A, anti-p75 IL-2R substantially inhibited the IL-2-induced cyto-
toxicity against an NK-resistant target, with maximal inhibition at lower concentra-
tions of IL-2. Anti-p55 IL-2R alone had no affect on IL-2-induced cytotoxicity, as
reported previously (7, 8). However, combining both anti-p55 IL-2R and anti-p75
IL-2R mAb did inhibit induction of cytotoxicity more efficiently than anti-p75 IL-
2R alone. Thus, although no p55 IL-2R was detected on the CD16+ NK popula-
tion by flow cytometry, low levels of this receptor may be present and functionally
active. Neither anti-p75 IL-2R nor anti-p55 IL-2R mAb affected cytotoxicity against
K562 mediated by unstimulated NK cells (not shown). Consistent results were ob-
served using NK cells from 5 donors. IL-2 induced proliferation of low buoyant den-
sity lymphocytes (Fig. 2 C) and FRCS purified NK cells (Fig. 2 D) was partially
inhibited by anti-p75 IL-2R or anti-p55 IL-2R mAb alone, but maximal inhibition
was observed by combining both antibodies. Culture of NK cells in rIL-2 induces
expression of p55 IL-2R on NK cells, resulting in the formation ofhigh affinity IL-
2R (10, 16) .
Stimulation of NK cells with IL-2 results in the rapid induction ofa newly synthe-
sized cell surface activation antigen, Leu-23 (CD69) (9). Leu-23 is a disulfide-linked
homodimer that is phosphorylated and expressed within a few hours after lympho-
cyte activation (9). >90% of NK cells express Leu-23 after exposure to IL-2, indi-
cating that these cells are functionally responsiveto this signal. To determine whether
the IL-2-mediated induction of Leu-23 is transmitted through the p75 IL-2R, resting
NK cells were cultured in IL-2 in the presence or absence of anti-p75 IL-2R or anti-
p55 IL-2R mAb. As shown in Fig. 3, induction of Leu-23 was completely inhibited
by anti-p75 IL-2R, but was unaffected by anti-p55 IL-2R. In summary, results from
the present studies directly implicate the p75 IL-2R as the structure predominantly
responsible for IL-2 activation of NK cells.
FIGURE 3.
￿
Inhibition ofCD69
e
￿
induction. Lowbuoyantdensity
rIL-2 " s.U-p751L-2R
￿
peripheral blood lymphocytes,
enriched for NK cells (-40%
u-z " .pa-pssu-zR
￿
CM-, C"16'), were cultured
for 18 h with or without 200
U/ml rIL-2 in the absence or
presence of isotype-matched
control Ig, anti-p55 IL-2R or
anti-p75 IL-2R (mAB concen-
Fluorescence (4 log Decade)
￿
Fluorescence (4 log Decades)
￿
tration, 10 h.g/ml). Cells were
harvested andstained with PE-
conjugated anti-Leu-23 (CD69) mAb and FITC-conjugated anti-Leu-lla (CD16). An electronic gate
was set on CD16' (i.e., FITC stained) cells and data were reprocessed to determinetheamount of CD69
expressed on the NK cells. (A) Histograms of CD69 fluorescence from NK cells cultured overnight in
"medium" or "rIL-2" with IgG1 control mAb. Histograms of cells stained with PE-conjugated control
IgGl mAbwere identical to the"medium" histogram(not shown). (B)Histograms ofCD69 fluorescence
from NK cells cultured overnight in rIL-2 with anti-p75 IL-2Ror with anti-p55 IL-2R mAb. Histo-
grams of cells stained with PE-conjugated control IgGl mAb were identical to the"rIL-2 + anti-p75"
histogram (not shown).
M.M.Summary
The IL-2R is composed of at least two subunits, the p55 (CD25/Tac) and p75
glycoproteins . The p75 IL-2R is expressed preferentially on resting human periph-
eral blood NK cells, but is not detected on substantial proportions of T and B lym-
phocytes, monocytes, or granulocytes. Anti-p75 IL-2R mAb substantially inhibits
the early events associated with NK cell activation by IL-2, including inhibition of
cytotoxic activity and induction of the CD69 early activation antigen. While anti-
p55 IL-2R mAb alone failed to substantially inhibit the initial events of IL-2 stimu-
lation, maximal inhibition ofIL-2-induced cytotoxicity and proliferation was achieved
by combining both anti-p55 IL-2R and anti-p75 IL-2R. Collectively, results from
the present studies directly implicate the p75 IL-2R as the structure predominantly
responsible for IL-2 activation of NK cells.
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